{"id":"Z10","lang":"zh","question":"台康生技的 EG12014 是什麼藥？跟 Sandoz 有什麼授權和銷售關係？","answer":[{"text":"EG12014 是台康生技的 trastuzumab 生物相似藥，2023 年公司公告指出它已取得歐盟上市許可。","fact_ids":["f1"]},{"text":"該公告列台康負責開發與製造、Sandoz 負責授權地區商業化，並列台灣、中國、俄羅斯及部分亞洲國家為排除地區。","fact_ids":["f2","f3"]},{"text":"2019 年簽約公告揭露付款類型包括簽約金、里程碑與銷售利潤分成。","fact_ids":["f4"]}],"facts":[{"id":"f1","claim":"藥物及歐盟許可","value":"EG12014，trastuzumab biosimilar；歐盟上市許可","as_of":"2023-11-17","source":"https://www.eirgenix.com/data-112206","quote":"trastuzumab biosimilar medicine (EG12014"},{"id":"f2","claim":"角色分工","value":"台康：開發及製造；Sandoz：授權地區商業化","as_of":"2023-11-17","source":"https://www.eirgenix.com/data-112206","quote":"development and manufacturing"},{"id":"f3","claim":"2023公告排除地區","value":"台灣、中國、俄羅斯、部分亞洲國家","as_of":"2023-11-17","source":"https://www.eirgenix.com/data-112206","quote":"Taiwan, China, Russia"},{"id":"f4","claim":"付款類型","value":"upfront、milestones、profit share","as_of":"2019-04-30","source":"https://www.eirgenix.com/data-21310","quote":"profit share payments"}],"undisclosed":{"text":"本卡核對的公開公告沒有逐一列出「部分亞洲國家」，也沒有提供各項合約付款與利潤分成的精確金額或比率。","source":"https://www.eirgenix.com/data-112206","as_of":"2026-10-22","quote":"some Asian countries","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"answered","document_note":"2019簽約稿僅列China/Taiwan；本卡地區採2023較新公告，不將舊稿範圍當成當前完整條款。"}